Novo Nordisk has launched its once-weekly diabetes and weight-management drug Ozempic in India. The semaglutide-based GLP-1 agonist improves glycaemic control, supports weight loss and may reduce cardiovascular and kidney risks. Prices start at Rs 8,800 per month for the lowest dose
